<DOC>
	<DOCNO>NCT00004239</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase I trial study effectiveness 506U78 treat patient hematologic cancer kidney liver impairment .</brief_summary>
	<brief_title>506U78 Treating Patients With Hematologic Cancer Kidney Liver Impairment</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose 506U78 patient hematologic malignancy renal hepatic impairment . II . Establish dose guideline drug patient population . III . Determine toxicities pharmacokinetics drug patient . OUTLINE : Patients stratify 5 group accord renal hepatic function : Group 1 : Normal renal function normal hepatic function Group 2 : Moderate renal impairment normal hepatic function Group 3 : Severe renal impairment normal hepatic function Group 4 : End stage renal impairment normal hepatic function Group 5 : Normal renal function moderate hepatic impairment Group 1 : Patients receive 506U78 IV 2 hour day 1 , 3 , 5 . Groups 2-5 : Patients receive 506U78 IV 2 hour day 1 , 3 , 5 . Dose escalation occur independently treatment group . Cohorts 3-6 patient receive escalate dos 506U78 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . Treatment repeat every 4 week maximum 6 course absence unacceptable toxicity disease progression . PROJECTED ACCRUAL : Approximately 60 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm hematologic malignancy fail standard therapy standard therapy exists , include , limited , follow : Acute lymphocytic leukemia Acute myelogenous leukemia Chronic lymphocytic leukemia Chronic myelogenous leukemia Multiple myeloma NonHodgkin 's lymphoma Hodgkin 's disease No history CNS disease , include carcinomatous meningitis PATIENT CHARACTERISTICS : Age : 18 Performance status : CTC 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin : Groups 14 : Less 1.5 time upper limit normal ( ULN ) Group 5 : 1.54 time ULN Renal : Creatinine clearance : Groups 1 5 : Greater 50 mL/min Group 2 : 3050 mL/min Group 3 : Less 30 mL/min Group 4 : Less 30 mL/min , require dialysis Neurologic : No history grade 2 peripheral neuropathy No history seizure disorder No history neurologic dysfunction Other : Not pregnant nursing Fertile patient must use effective contraception HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy ( e.g. , interferon , monoclonal antibody ) No concurrent interleukin11 treatment prevention thrombocytopenia No concurrent prophylactic colony stimulate factor Chemotherapy : At least 4 week since prior chemotherapy ( 6 week melphalan , carmustine , mitomycin ) At least 72 hour since prior hydroxyurea No prior 506U78 No concurrent chemotherapy Endocrine therapy : At least 72 hour since prior glucocorticoid Concurrent continuation steroid adrenal failure allow No concurrent hormones except nondisease relate condition ( e.g. , insulin diabetes ) No concurrent dexamethasone steroidal antiemetic Radiotherapy : At least 4 week since prior radiotherapy No concurrent palliative radiotherapy No concurrent whole brain irradiation document CNS disease Surgery : Not specify Other : At least 72 hour since prior aspirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>